These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1040 related articles for article (PubMed ID: 30001569)

  • 1. The pharmacokinetics and the pharmacodynamics of cannabinoids.
    Lucas CJ; Galettis P; Schneider J
    Br J Clin Pharmacol; 2018 Nov; 84(11):2477-2482. PubMed ID: 30001569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabis sativa: Much more beyond Δ
    Alves P; Amaral C; Teixeira N; Correia-da-Silva G
    Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines.
    Arellano AL; Papaseit E; Romaguera A; Torrens M; Farré M
    CNS Neurol Disord Drug Targets; 2017; 16(5):554-566. PubMed ID: 28412920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabis, from plant to pill.
    Grof CPL
    Br J Clin Pharmacol; 2018 Nov; 84(11):2463-2467. PubMed ID: 29701252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaps in predicting clinical doses for cannabinoids therapy: Overview of issues for pharmacokinetics and pharmacodynamics modelling.
    Liu Z; Martin JH
    Br J Clin Pharmacol; 2018 Nov; 84(11):2483-2487. PubMed ID: 29766540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
    Anderson GD; Chan LN
    Clin Pharmacokinet; 2016 Nov; 55(11):1353-1368. PubMed ID: 27106177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
    Bansal S; Maharao N; Paine MF; Unadkat JD
    Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
    Qian Y; Markowitz JS
    Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
    Qian Y; Gurley BJ; Markowitz JS
    J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of cannabinoids.
    Grotenhermen F
    Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice.
    Iannotti FA; Pagano E; Moriello AS; Alvino FG; Sorrentino NC; D'Orsi L; Gazzerro E; Capasso R; De Leonibus E; De Petrocellis L; Di Marzo V
    Br J Pharmacol; 2019 May; 176(10):1568-1584. PubMed ID: 30074247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid-induced alterations in brain disposition of drugs of abuse.
    Reid MJ; Bornheim LM
    Biochem Pharmacol; 2001 Jun; 61(11):1357-67. PubMed ID: 11331071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting cannabis products to pharmaceutical drugs.
    Koltai H; Poulin P; Namdar D
    Eur J Pharm Sci; 2019 Apr; 132():118-120. PubMed ID: 30851400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics.
    Nahler G
    Pharmaceut Med; 2022 Apr; 36(2):99-129. PubMed ID: 35244889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material.
    De Backer B; Debrus B; Lebrun P; Theunis L; Dubois N; Decock L; Verstraete A; Hubert P; Charlier C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4115-24. PubMed ID: 19932642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis, cannabidiol and tetrahydrocannabinol in sport: an overview.
    Kennedy M
    Intern Med J; 2022 Sep; 52(9):1471-1477. PubMed ID: 35191178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.